Welcome!

News Feed Item

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

Summary

Uveitis is a serious eye condition that often results in permanent vision damage due to frequent recurrence even after treatment. It consists of a group of diseases that present with inflammation of the uvea, can occur in one or both eyes, and may also affect the adjacent tissues such as the retina, optic nerve, and vitreous humor. Symptoms may include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. Uveitis has a wide variety of causes such as autoimmune disorders, infectious agents, or toxins; however, the cause is often unknown for a significant proportion of the cases.

In 2012, GlobalData epidemiologists forecast the 6MM had 223,559 incident cases of uveitis, 75% of which (168,264 cases) occurred in the US. Incident cases in the 6MM are expected to increase slightly to 245,353 cases by 2022, at the rate of 0.97% per year. In 2012, the 6MM had 665,778 prevalent cases of uveitis, which will increase to 730,913 cases in 2022 at the rate of 0.98% per year. The US also had the largest proportion of prevalent cases in 2012 (53.69%, 357,483 cases) out of all markets covered in this analysis. The forecast further shows anterior uveitis is the most common form of uveitis and non-infectious uveitis is the most common etiology among the 6MM.

This forecast provides detailed, granular, and clinically relevant segmentations of uveitis cases. The segmentations will allow for improved understanding of the disease and the ability to focus on specific subgroups within the disease. The analysis is further strengthened by the adherence to the standard clinical reporting guidelines from the International Uveitis Study Group (IUSG) and Standardization of Uveitis Nomenclature (SUN) Working Group. Using standard guidelines across the 6MM allows for meaningful comparisons across the markets and ensures these results will be relevant in reference to future studies, as the use of the guidelines are becoming more common in epidemiological research.

Scope

- This report provides an overview of the risk factors, comorbidities and the global epidemiological trends for uveitis in the six major markets (6MM: US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year forecast of incident and prevalent cases of uveitis segmented by age, sex, primary anatomical location of inflammation (anterior, intermediate, posterior, panuveitis), and by etiology (infectious, non-infectious, idiopathic). Incident cases are further segmented by course of disease (acute, recurrent, chronic) and by severity (mild, moderate, severe).
- The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global uveitis market.
- Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for uveitis therapeutics in each of the markets covered.
- Identify the number of uveitis cases in each anatomical location category and in each etiology.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Smoking increases risk of uveitis and increases complications 11
3.2.2 Juvenile idiopathic arthritis patients need regular ophthalmologic screenings 12
3.2.3 HLA-positive antigens are linked to certain types of uveitis 13
3.2.4 Uveitis is associated with various autoimmune, neurological, and infectious diseases 13
3.3 Global Trends 15
3.3.1 US 17
3.3.2 5EU 20
3.4 Forecast Methodology 22
3.4.1 Sources Used 25
3.4.2 Sources Not Used 30
3.4.3 Forecast Assumptions and Methods, Incident Cases 31
3.4.4 Forecast Assumptions and Methods, Prevalent Cases 32
3.4.5 Forecast Assumptions and Methods, Etiological and Anatomical Distribution 33
3.4.6 Forecast Assumptions and Methods, Course of Disease 36
3.4.7 Forecast Assumptions and Methods, Disease Severity 37
3.5 Epidemiological Forecast of Uveitis (2012-2022) 37
3.5.1 Incident Cases of Uveitis 37
3.5.2 Age-Specific Incident Cases of Uveitis 39
3.5.3 Sex-Specific Incident Cases 41
3.5.4 Age-Standardized Incidence Rates 42
3.5.5 Incident Cases by Anatomical Location 43
3.5.6 Incident Cases Segmented by Etiology 45
3.5.7 Course of Disease of Incident Uveitis Cases 48
3.5.8 Severity of Incident Uveitis Cases 50
3.5.9 Prevalent Cases of Uveitis 51
3.5.10 Age-Specific Prevalent Cases of Uveitis 53
3.5.11 Sex-Specific Prevalent Cases of Uveitis 54
3.5.12 Prevalent Cases by Anatomical Location 56
3.5.13 Prevalent Cases by Etiology 57
3.6 Discussion 59
3.6.1 Epidemiological Forecast Insight 59
3.6.2 Limitations of the Analysis 59
3.6.3 Strengths of the Analysis 61
4 Appendix 62
4.1 Bibliography 62
4.2 About the Authors 67
4.2.1 Epidemiologists 67
4.2.2 Reviewers 67
4.2.3 Global Director of Epidemiology and Health Policy 69
4.2.4 Global Head of Healthcare 69
4.3 About GlobalData 70
4.4 About EpiCast 70
4.5 Disclaimer 71

List of Tables

Table 1: Diseases Most Frequently Associated with Uveitis 14
Table 2: Distribution of Uveitis by Anatomical Location in Community and Referral Centers 20
Table 3: Distribution of Uveitis Cases by Anatomical Location of Inflammation, Europe 22
Table 4: IUSG/SUN Working Group Classification of Uveitis by Anatomical Location 23
Table 5: Clinical Classifications of Uveitis 23
Table 6: 6MM, Sources of Incidence and Prevalence of Uveitis in the 6MM 24
Table 7: Italy, Anatomy Classification Calculation 34
Table 8: US, Anatomical Locations of Uveitis for Incident and Prevalent Cases 36
Table 9: 6MM, Incident Cases of Uveitis, N (Column %), Select Years 2012-2022 38
Table 10: 6MM, Age-Specific Incident Cases of Uveitis, N (Row %), 2012 39
Table 11: 6MM, Sex-Specific Incident Cases of Uveitis, N (Row %), 2012 41
Table 12: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N (Row %), 2012 44
Table 13: 6MM, Incident Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 46
Table 14: 6MM, Incident Cases of Uveitis Segmented by Etiology and Anatomical Location, N, 2012 47
Table 15: 6MM, Incident Cases of Uveitis by Course of Disease, N (Row %), 2012 48
Table 16: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 50
Table 17: 6MM, Prevalent Cases of Uveitis, N (Column %), Select Years, 2012-2022 52
Table 18: 6MM, Age-Specific Prevalent Cases of Uveitis, N (Row %), 2012 53
Table 19: 6MM, Sex-Specific Prevalent Cases of Uveitis, N (Row %), 2012 55
Table 20: 6MM, Prevalent Cases of Uveitis by Anatomical Location of Inflammation, N (Row %), 2012 56
Table 21: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 57
Table 22: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Anatomical Location, 2012 58

List of Figures

Figure 1: US, Age Distribution of Study Populations Compared with the US General Population 18
Figure 2: US, Sex-Ratio of Study Populations Compared with the US General Population 19
Figure 3: 6MM, Incident Cases of Uveitis, N, 2012-2022 38
Figure 4: 6MM, Age-Specific Incident Cases of Uveitis, N, 2012 40
Figure 5: 6MM, Sex-Specific Incident Cases of Uveitis, N, 2012 42
Figure 6: 6MM, Age-Standardized Uveitis Incidence, Cases per 100,000 Population, Men and Women, 2012 43
Figure 7: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N, 2012 45
Figure 8: 6MM, Incident Cases of Uveitis by Course of Disease, N, 2012 49
Figure 9: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 51
Figure 10: 6MM, Prevalent Cases of Uveitis, N, 2012-2022 52
Figure 11: 6MM, Age-Specific Prevalent Cases of Uveitis, N, 2012 54
Figure 12: 6MM, Sex-Specific Prevalent Cases of Uveitis, N, 2012 55

Read the full report:
EpiCast Report: Uveitis - Epidemiology Forecast to 2022
http://www.reportbuyer.com/pharma_healthcare/healthcare/epicast_report_uveitis_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, introduced two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a multip...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5–7, 2018, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users that have experienced products and services first-hand and have an interest in letting other potential buye...